Liquid Biopsy Offers a Non-Invasive Path to Precision Treatment for Bladder Cancer

Bladder cancer remains one of the most challenging malignancies in modern urology, and a newly published comprehensive review in the Journal of Translational Medicine argues that the field is standing at the threshold of a diagnostic revolution. The review, led by Can Chen and colleagues working across the National Cancer Center in Beijing, Tsinghua University and the Second Affiliated Hospital of Zunyi Medical University, synthesizes a decade of evidence showing that liquid biopsy, the analysis of tumor-derived material circulating in blood and urine, could transform how urothelial carcinoma is detected, monitored and treated. The authors contend that current standards of care, which rely heavily on cystoscopy and tissue biopsy, are invasive, costly and structurally incapable of capturing the full biological picture of a patient’s disease, and that minimally invasive biomarkers are now urgently needed to close that gap.

The clinical burden that motivates this push is substantial. Bladder cancer, the most common form of urothelial carcinoma, is characterized by high rates of late diagnosis and strikingly frequent recurrence, forcing patients into years of repeated surveillance procedures. Cystoscopy, the endoscopic examination of the bladder that remains the diagnostic gold standard, is uncomfortable, expensive and offers only a visual snapshot of the tumor at a single moment in time. Tissue biopsy, meanwhile, samples only a fragment of the lesion, leaving the considerable spatial heterogeneity of the disease hidden from view. Neither approach lends itself naturally to the kind of longitudinal monitoring that bladder cancer patients, who face lifelong recurrence risk, genuinely require. It is precisely these constraints, the review argues, that have created the opening for liquid biopsy to move from research curiosity to clinical mainstay.

At the heart of the liquid biopsy concept are three principal analytes: circulating tumor DNA, circulating tumor cells and extracellular vesicles. Circulating tumor DNA consists of short fragments of tumor genome shed into the bloodstream, carrying with them the mutations, copy number variations and methylation patterns that define the original malignancy. Because it can be sampled repeatedly through a simple blood draw, ctDNA offers a dynamic, real-time portrait of tumor burden and evolution. The review details how technological advances, including droplet digital PCR and next-generation sequencing, have progressively lowered the detection limits for these faint molecular signals, enabling clinicians to identify residual disease at levels far below what imaging or cytology can resolve.

Circulating tumor cells, the second pillar, provide something ctDNA cannot: intact living cells that retain their morphology, protein expression and functional behavior. These cells, which detach from the primary tumor and travel through the circulation, are thought to be the seeds of metastasis. Capturing and characterizing them allows researchers to interrogate the epithelial-to-mesenchymal transition, the process by which cancer cells acquire invasive and migratory properties, and to profile the cell surface markers that may predict how aggressive a given patient’s disease will become. The review emphasizes that CTC enumeration and molecular characterization hold particular promise for prognostic stratification, helping to separate patients at high risk of progression from those who may be spared aggressive intervention.

Extracellular vesicles, the third and perhaps most versatile analyte, are nanoscale membrane-bound particles released by tumor cells into their surroundings. Far from being cellular debris, these vesicles act as intercellular messengers, ferrying proteins, lipids and nucleic acids between cells and actively shaping the tumor microenvironment. Within them travel microRNAs, long non-coding RNAs and circular RNAs, a cargo of regulatory molecules whose signatures can reveal both the presence of cancer and the state of the immune response against it. The review also highlights tumor-educated platelets, blood platelets that have been reprogrammed by tumor-derived signals and whose RNA profiles offer an additional, largely tumor-independent window into disease status.

What unites these analytes is their application across the entire arc of cancer care. In early detection, urine-based and blood-based biomarker panels are being developed to identify urothelial carcinoma before it becomes symptomatic, potentially reducing dependence on repeated invasive surveillance in patients with a history of the disease. In prognostic stratification, the review consolidates evidence linking ctDNA levels, CTC counts and vesicle cargo to progression-free and overall survival, suggesting that a single blood draw could one day inform how intensively a newly diagnosed patient is treated. In treatment response monitoring, serial liquid biopsy measurements can reveal whether neoadjuvant chemotherapy is working within weeks of initiation, long before radiographic scans could show any change, allowing ineffective regimens to be abandoned and alternatives started sooner.

The review gives particular attention to the intersection of liquid biopsy with immunotherapy, an area of intense clinical interest in metastatic urothelial carcinoma. Immune checkpoint inhibitors have reshaped treatment for advanced disease, but only a subset of patients respond, and clinicians currently lack reliable tools to identify responders in advance. Liquid biopsy offers several routes into this problem: ctDNA dynamics during therapy appear to correlate with response and survival, while the molecular features of circulating analytes can be used for immunophenotyping, characterizing the inflammatory and immune landscape of the tumor without touching it. The authors argue that such non-invasive immunophenotyping could eventually guide the selection of patients for checkpoint inhibitor therapy and for emerging combinations, moving the field closer to truly individualized immunotherapy decisions.

None of this, the review is careful to stress, is yet a finished story. Significant challenges persist before liquid biopsy can be integrated routinely into bladder cancer management. Analytical hurdles include the low fraction of tumor-derived DNA in early disease, the lack of standardized protocols for sample collection, processing and quality control, and variability among the many sequencing and capture platforms now on the market. Clinical hurdles include the absence of large, prospective, multicenter validation trials demonstrating that liquid biopsy-guided decisions genuinely improve patient outcomes, and unresolved questions about which analyte, or which combination of analytes, delivers the greatest value for each clinical scenario. Cost and accessibility also remain concerns if the technology is to benefit patients beyond specialized academic centers.

The translational path forward, as the authors outline it, involves converging several emerging technologies. Machine learning algorithms are increasingly being applied to multi-analyte datasets to extract diagnostic and prognostic signals that no single marker could provide, and whole-genome sequencing approaches are expanding the range of detectable alterations beyond the hotspots targeted by conventional panels. The review envisions a future in which a bladder cancer patient’s trajectory, from initial suspicion through treatment and into long-term surveillance, is punctuated not by repeated cystoscopies but by serial molecular snapshots drawn from blood and urine, with minimal residual disease detected and treated before it ever becomes visible on a scan.

For a disease defined by recurrence and heterogeneity, the appeal of that vision is easy to understand. The review’s synthesis makes the case that the scientific groundwork, sensitive detection platforms, biologically informative analytes and accumulating clinical evidence, has largely been laid. What remains is the disciplined work of validation, standardization and integration into treatment guidelines. If that work succeeds, liquid biopsy could shift bladder cancer care from a reactive cycle of detection and resection toward a proactive, molecularly informed model of precision oncology, in which each patient’s therapy is continuously calibrated to the evolving biology of their tumor, sampled not with a scalpel but with a needle and a vial.

Subject of Research: Liquid biopsy biomarkers for early detection, monitoring and precision treatment of bladder cancer

Article Title: Liquid biopsy in bladder cancer: towards precision oncology

Article References: Chen, C., Yang, Y., Chen, Z., Li, X., Zhu, Y., Zhai, Y., Zheng, J., Dai, X., Zhou, J.-G., Ma, H., & Ye, X. (2026). Liquid biopsy in bladder cancer: towards precision oncology. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08892-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08892-7

Keywords: liquid biopsy, bladder cancer, urothelial carcinoma, circulating tumor DNA, circulating tumor cells, extracellular vesicles, precision oncology, minimal residual disease, immune checkpoint inhibitors, tumor-educated platelets, next-generation sequencing, biomarkers